Loading...
•
Jun 30, 2021
Ionis Q2 2021 Earnings Report
Ionis reported second quarter financial results, highlighted by progress in Phase 3 milestones for multiple drugs and expansion of drug delivery capabilities.
Key Takeaways
Ionis Pharmaceuticals reported $126 million in total revenues for Q2 2021. The company is on track to achieve its 2021 revenue guidance of more than $600 million. Key milestones included the completion of dosing in the tofersen Phase 3 VALOR study and full enrollment in the eplontersen Phase 3 NEURO-TTRansform study.
Total revenues reached $126 million.
Operating expenses were $199 million on a GAAP basis.
Net loss was $81 million on a GAAP basis.
Cash and investments totaled $2.1 billion at the end of the quarter.
Ionis
Ionis
Ionis Revenue by Segment
Revenue by Segment
SPINRAZA royalties Revenue
CapyFin.comTEGSEDI and WAYLIVRA Revenue
CapyFin.com Forward Guidance
Ionis expects to achieve its 2021 revenue guidance of more than $600 million and anticipates increased R&D revenue in the second half of the year. The company is revising its 2021 operating expense and net loss guidance due to the license of Bicycle’s technology.
Revenue & Expenses
Visualization of income flow from segment revenue to net income